MacroGenics, Inc.: updates and filings

MGNXNASDAQHealthcare · Pharmaceutical Preparations

Price

$1.99

November 19, 2026Market cap $126M

What Ploutos Investor adds for MacroGenics

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 15 fiscal years, from 2011
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

Notes on these figures

  • The interest the company pays is far more than the debt we can read would cost, so part of its borrowing is missing from the figures. We leave out the debt, net cash, enterprise value and the multiples built on them.

What comes next, and what happened

Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.

Next results

in 85 daysAround Feb 12, 2027 · for Q4 2026

last Nov 12, 2026next Feb 12, 2027

A rough estimate from when it has reported before, which has varied. The company announces the date itself.

Its SEC filings

What it has filed lately, newest first, linked to the document itself.

Mar 9, 2026 latest annualNov 12, 2026 latest quarterly
  • Nov 16, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Nov 13, 2026Regulation FD disclosure
    Form8-K
  • Nov 12, 2026Results of operations
    Form8-K
  • Nov 12, 2026Quarterly reportfor the period to Sep 30, 2026
    Form10-Q
  • Nov 3, 2026Officer or director change, Regulation FD disclosure
    Form8-K
  • Oct 23, 2026Other material events
    Form8-K
  • Sep 3, 2026Shares registered for employees
    FormS-8
  • Sep 3, 2026Financial statements and exhibits (amendment)
    Form8-K/A
  • Aug 14, 2026Quarterly reportfor the period to Jun 30, 2026
    Form10-Q
  • Aug 14, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Aug 13, 2026Results of operations
    Form8-K
  • Aug 3, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Jul 29, 2026Over-5% holder statement (passive)
    FormSCHEDULE 13G
  • Jul 23, 2026Other material events
    Form8-K
  • Jul 20, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Jul 8, 2026Officer or director change
    Form8-K
  • Jul 7, 2026Acquisition or disposal of assets, Regulation FD disclosure
    Form8-K
  • Jun 5, 2026Over-5% holder statement (passive)
    FormSCHEDULE 13G
  • May 20, 2026Shareholder vote
    Form8-K
  • May 15, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • May 14, 2026Over-5% holder statement (passive)
    FormSCHEDULE 13G
  • May 14, 2026Over-5% holder statement (passive)
    FormSCHEDULE 13G
  • May 13, 2026Results of operations
    Form8-K
  • May 13, 2026Quarterly reportfor the period to Mar 31, 2026
    Form10-Q
  • May 12, 2026Material agreement entered, Regulation FD disclosure
    Form8-K

From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Nov 12, 2003.

The full analysis

What do MacroGenics's filings show?

The filings are where every one of MacroGenics's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

All filings on EDGAR

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.